Nanotechnology for cancer screening and diagnosis: from innovations to clinical applications

Zeineldin, Reema

doi:10.1016/b978-0-08-102983-1.00010-7

Cited by 5 publications

(11 citation statements)

References 242 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…145,184 The use of multimodal tracking agents is beneficial for image-guided drug delivery and obtains the precise information about biodistribution and the specific accumulation of nanocarriers in the tumor sites. 15,185 Imageguided chemo-and photothermal cancer therapy is among the hot research topics (Figure 10). 186,187 For example, an interesting theranostic nanoplatform has been recently developed by the coincorporation of gold nanorods and gadolinium as the PTT and MRI agents, respectively, into MSNPs (Figure 10A).…”

Section: Cancer Theranosticsmentioning

confidence: 99%

“…Various components such as drugs, energy sources, imaging probes, stimuli-sensitive elements, and targeting agents are assembled into a nanoplatform to obtain these integrated nanostructures . Different NPs, including magnetic, , gold, , polymer, , and silica , NPs, and fluorescent QDs and CDs have been used for the development of theranostic NPs . Recently, some advanced nanomaterials with simultaneous optical, magnetic, and therapeutic activities have also been reported and used to develop multifunctional nanostructures. ,, Design and development of smart theranostic NPs with specific targeting and labeling of cancer cells, efficient and controlled delivery of therapeutic agents into the specific sites, and following up the treatment progress over time are fields of interest .…”

Section: Cancer Theranosticsmentioning

confidence: 99%

“…The advent of theranostic NPs has opened a new avenue toward personalized medicine, including early detection and monitoring of the disease progression, selecting efficient therapeutic agents, monitoring the therapy response, and assessing the side effects. , The use of multimodal tracking agents is beneficial for image-guided drug delivery and obtains the precise information about biodistribution and the specific accumulation of nanocarriers in the tumor sites. , Image-guided chemo- and photothermal cancer therapy is among the hot research topics (Figure ). , For example, an interesting theranostic nanoplatform has been recently developed by the coincorporation of gold nanorods and gadolinium as the PTT and MRI agents, respectively, into MSNPs (Figure A) .…”

Section: Cancer Theranosticsmentioning

confidence: 99%

“…9,13,14 These collaborations are necessary to obtain the most effective nanotherapeutics with the desirable performance, minimum side effects, appropriate biodistribution, and optimum clearance. 15 Finally, the manufacturing engineering for the commercial production of nanotherapeutics with high quality and low cost is very important. 16 Nanomedicine is actively involved in the development of new approaches for the sensitive and early detection of cancer.…”

Section: Introductionmentioning

confidence: 99%

“…Owing to the high complexity of a biological (tumor or disease) microenvironment, a very close collaboration between the scientists of different specialties, including chemistry, nanotechnology, biomaterials, engineering, biology, and medicine, as well as the pharmaceutical industry is essential to develop NPs with high potential clinical applications, especially cancer treatment. ,, These collaborations are necessary to obtain the most effective nanotherapeutics with the desirable performance, minimum side effects, appropriate biodistribution, and optimum clearance . Finally, the manufacturing engineering for the commercial production of nanotherapeutics with high quality and low cost is very important …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Recent Advances in Nanomaterials Development for Nanomedicine and Cancer

Kajani

Javanmard

Asadnia

et al. 2021

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Cancer is considered one of the leading causes of death, with a growing number of cases worldwide. However, the early diagnosis and efficient therapy of cancer have remained a critical challenge. The emergence of nanomedicine has opened up a promising window to address the drawbacks of cancer detection and treatment. A wide range of engineered nanomaterials and nanoplatforms with different shapes, sizes, and composition has been developed for various biomedical applications. Nanomaterials have been increasingly used in various applications in bioimaging, diagnosis, and therapy of cancers. Recently, numerous multifunctional and smart nanoparticles with the ability of simultaneous diagnosis and targeted cancer therapy have been reported. The multidisciplinary attempts led to the development of several exciting clinically approved nanotherapeutics. The nanobased materials and devices have also been used extensively to develop point-of-care and highly sensitive methods of cancer detection. In this review article, the most significant achievements and latest advances in the nanomaterials development for cancer nanomedicine are critically discussed. In addition, the future perspectives of this field are evaluated.

show abstract

Section: Cancer Theranosticsmentioning

confidence: 99%

Section: Cancer Theranosticsmentioning

confidence: 99%

Section: Cancer Theranosticsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Recent Advances in Nanomaterials Development for Nanomedicine and Cancer

Kajani

Javanmard

Asadnia

et al. 2021

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

show abstract

Nanobiotechnology for Cancer Diagnosis

Gopal,

Mahmood,

Sofian

et al. 2024

Interdisciplinary Biotechnological Advances

View full text Add to dashboard Cite

Design of a Ratiometric Plasmonic Biosensor for Herceptin Detection in HER2-Positive Breast Cancer

Shahbazi

Zare‐Dorabei

Naghib

2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Breast cancer is the most common cause of cancer death in women; therefore, its early detection and treatment are crucial. To achieve this goal, we designed an optical sensor based on direct interaction of trastuzumab [Herceptin (HER)], a monoclonal antibody used to treat HER2-positive breast cancer, with plasmonic nanoparticles. Surface-modified gold nanoparticles (AuNPs) have gained considerable attention in biosensing techniques over the last years, which actuated these nanoparticles to the heart of various biosensing notions. We have exploited the localized surface plasmon resonance (LSPR) of gold nanoparticles to determine HER in human serum. AuNPs were decorated with negatively charged citrate ions, yielding enhanced direct-surface interaction with HER antibodies. The AuNPs are mixed with silver nanoparticles (AgNPs) in an optimized ratio to increase selectivity and sensitivity further. AuNPs detect the HER antibodies using LSPR, whereas AgNPs help monitor interferences’ effect on the sensing media. The three effective factors in HER sensing, including the nanoparticle ratio, temperature, and pH were optimized via response surface methodology (RSM) based on the central composite design (CCD). The sensor’s response toward HER was achieved in the linear range of 0.5 × 10–7 to 40 × 10–7 M with the detection limit of 3.7 × 10–9 M and relative standard deviation (RSD) less than 5%. The selectivity of the LSPR sensor was assessed by monitoring its response toward HER in the presence of other biological molecules with similar physicochemical properties. Rapid response time (less than 1 min), selectivity, and the simplicity of the developed LSPR-based sensor are the key advantages of the developed sensor.

show abstract

Nanotechnology for cancer screening and diagnosis: from innovations to clinical applications

Cited by 5 publications

References 242 publications

Recent Advances in Nanomaterials Development for Nanomedicine and Cancer

Recent Advances in Nanomaterials Development for Nanomedicine and Cancer

Nanobiotechnology for Cancer Diagnosis

Design of a Ratiometric Plasmonic Biosensor for Herceptin Detection in HER2-Positive Breast Cancer

Contact Info

Product

Resources

About